Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Oncofertility w praktyce klin.
  • Obniżka
50 Studies Every Psychiatrist Should Know

50 Studies Every Psychiatrist Should Know

9780190625085
407,16 zł
366,44 zł Zniżka 40,72 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 366,44 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
50 Studies Every Psychiatrist Should Know presents key studies that have shaped the practice of psychiatry. Selected using a rigorous methodology, the studies cover topics including:: psychotic disorders, depressive disorders, womens mental health, child and adolescent disorders, and epidemiological studies. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. An illustrative clinicalcase concludes each review, followed by brief information on other relevant studies. This book is a must-read for health care professionals and anyone who wants to learn more about the data behind clinical practice.
Szczegóły produktu
OUP USA
84844
9780190625085
9780190625085

Opis

Rok wydania
2018
Numer wydania
1
Oprawa
miękka foliowana
Liczba stron
376
Wymiary (mm)
156 x 235
Waga (g)
635
  • Section 1: Anxiety Disorders; Chapter 1: Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder; Amanda Sun and Tobias Wasser; Chapter 2: Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia; Erin Habecker and Tobias Wasser; Section 2: Bipolar Disorder; Chapter 3: Lithium Plus Valproate Combination Versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE); Jo?o Paulo De Aquino and Robert Beech; Chapter 4: Mood Stabilizer Monotherapy vs. Adjunctive Antidepressant for Bipolar Depression: The STEP-BD Trial; Jo?o Paulo De Aquino and Robert Beech; Chapter 5: Suicide Risk in Bipolar Disorder: Comparing Lithium, Divalproex, and Carbamazepine; Rachel Katz and Robert Beech; Chapter 6: The Long-term Natural History of Bipolar I Disorder; Zachary Engler and Robert Beech; Section 3: Child and Adolescent Disorders; Chapter 7: The Multimodal Treatment Study of Children with Attention Deficit/Hyperactivity Disorder (MTA); Michael Hochman, edited by Michael H. Bloch; Chapter 8: Adolescents with SSRI-Resistant Depression: The TORDIA Trial; Amalia Londono Tobon and Hanna Stevens; Chapter 9: Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study; J. Corey Williams and Hanna Stevens; Chapter 10: Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety: CAMS; David Saunders, Jerome Taylor, and Andres Martin; Chapter 11: Predictors of Suicidal Events: The Treatment of Adolescent Suicide Attempters study (TASA); Michael Maksimowski and Zheala Qayyum; Chapter 12: Cognitive Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents with OCD; Falisha Gilman and Zheala Qayyum; Chapter 13: Initial Treatment of Bipolar I Disorder in Children and Adolescents: The TEAM Trial; Stephanie Ng and Andres Martin; Chapter 14: The Treatment for Adolescents with Depression Study (TADS); Zachary Engler and Zheala Qayyum; Section 4: Cognitive Disorders: Delirium/Dementia; Chapter 15: Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease: CATIE-AD; Adam Mecca and Rajesh R. Tampi; Chapter 16: Risk of Death with Atypical Antipsychotic Medications for Dementia; Adam Mecca and Rajesh R. Tampi; Chapter 17: Treatment of Delirium in Hospitalized AIDS Patients: A Double-Blind Trial of Haloperidol, Chlorpromazine, and Lorazepam; Amanda Sun and Rajesh R. Tampi; Chapter 18: Memantine in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil; Brandon M. Kitay and Rajesh R. Tampi; Section 5: Epidemiology; Chapter 19: Global Burden of Mental and Substance Use Disorders; Stephanie Yarnell and Ellen Edens; Chapter 20: Prevalence and Severity of Psychiatric Comorbidities: The National Comorbidity Survey Replication (NCS-R); Stephanie Yarnell and Ellen Edens; Section 6: Insomnia; Chapter 21: Behavioral and/or Pharmacotherapy for Older Patients with Insomnia; Robert Ross and Rajesh R. Tampi; Section 7: Major Depressive Disorder; Chapter 22: Treatment of Depression in Patients with Alcohol or Drug Dependence: A Meta-Analysis; J. Corey Williams and Gustavo Angarita-Africano; Chapter 23: Suicidality in Pediatric Patients Treated with Antidepressant Drugs: FDA Meta-analysis; David Saunders and Michael H. Bloch; Chapter 24: National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research Program; Joseph Taylor and Robert Ostroff; Chapter 25: Efficacy and Safety of Electroconvulsive Therapy in Depressive Disorders: A Systematic Review and Meta-analysis; Joseph Taylor and Robert Ostroff; Chapter 26: Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration; Michael Maksimowski and Zheala Qayyum; Chapter 27: Sequenced Treatment Alternatives to Relieve Depression: STAR*D; Eric Lin and Pochu Ho; Chapter 28: Cognitive Therapy vs. Medication in the Treatment of Moderate to Severe Depression; Daniel Barron and Robert Ostroff; Section 8: Obsessive Compulsive Disorder; Chapter 29: Exposure and Ritual Prevention, Clomipramine, or Their Combination for Obsessive-Compulsive Disorder; Brandon M. Kitay and Michael H. Bloch; Chapter 30: Meta-analysis of the Dose-response relationship of SSRIs in adult patients with Obsessive Compulsive Disorder; Eunice Yuen and Michael H. Bloch; Section 9: Personality Disorders; Chapter 31: Psychotherapy for Borderline Personality Disorder: A Multiwave Study; David Grunwald, Erica Robinson, and Sarah Fineberg; Chapter 32: Dialectical Behavior Therapy vs. Community Treatment by Experts for Reducing Suicidal Behaviors Among Patients with Borderline Personality Disorder; David Saunders, Erica Robinson, and Sarah Fineberg; Chapter 33: Ten-Year Course of Borderline Personality Disorder: The Collaborative Longitudinal Personality Disorders Study; Kevin Johnson, Erica Robinson, and Sarah Fineberg; Section 10: Psychiatry in Primary Care; Chapter 34: Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul Study; Amalia Londono Tobon and Catherine Chiles; Chapter 35: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial; Nikhil Gupta and Catherine Chiles; Section 11: Womens Mental Health; Chapter 36: Buprenorphine vs. Methadone During Pregnancy: The MOTHER Trial; Rachel Wurmser and Kirstin Wilkins; Section 12: Schizophrenia; Chapter 37: QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients; Amanda Sun and Vinod H. Srihari; Chapter 38: Tardive Dyskinesia with Atypical vs. Conventional Antipsychotic Medications; Emma Lo and Cenk Tek; Chapter 39: Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1; Chadrick Lane and Mohini Ranganathan; Chapter 40: Clozapine for Treatment-Resistant Schizophrenia; Chadrick Lane and Vinod H. Srihari; Chapter 41: Effectiveness of clozapine vs. other atypical antipsychotics: Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE); Eunice Yuen and Cenk Tek; Chapter 42: Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death; Hamilton Hicks and Cenk Tek; Chapter 43: Switching Antipsychotics to Reduce Metabolic Risk: The CAMP Trial; Eric Lin and John Cahill; Chapter 44: Cost Utility of Atypical Antipsychotics: CUtLASS-1; Nikhil Gupta and John Cahill; Chapter 45: North American Prodrome Longitudinal Study; Nikhil Gupta and Vinod H. Srihari; Chapter 46: Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT); Daniel Barron and Noah Capurso; Chapter 47: A Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia; Stephanie Ng and Cenk Tek; Section 13: Substance Use Disorders; Chapter 48: Methadone Maintenance vs. Detoxification and Psychosocial Treatment for Opioid Dependence: The M180 Study; Hamilton Hicks and Srinivas Muvvala; Chapter 49: Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study; Kevin Johnson and Srinivas Muvvala; Chapter 50: Levomethadyl acetate vs. Buprenorphine vs. Methadone for Opioid Dependence; Robert Ross and Brian Fuehrlein;
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów